Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Century Therapeutics (NASDAQ:IPSC – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
Risk & Volatility
Dianthus Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.
Profitability
This table compares Dianthus Therapeutics and Century Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
| Century Therapeutics | N/A | -49.51% | -38.09% |
Institutional and Insider Ownership
47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for Dianthus Therapeutics and Century Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
| Century Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Dianthus Therapeutics currently has a consensus price target of $128.54, indicating a potential upside of 55.43%. Century Therapeutics has a consensus price target of $4.75, indicating a potential upside of 225.34%. Given Century Therapeutics’ higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Dianthus Therapeutics.
Valuation & Earnings
This table compares Dianthus Therapeutics and Century Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $2.04 million | 2,221.55 | -$162.34 million | ($4.15) | -19.93 |
| Century Therapeutics | $109.16 million | 2.42 | -$9.58 million | ($0.93) | -1.57 |
Century Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Century Therapeutics beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
About Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
